| 2025-01-30 15-28-05 | Urolithin A reduces the number of TUNEL-positive cells in the Nucleus Pulposus at a dose of 25 mg/kg/day when taken for 4 weeks after an Intervertebral Disc (IVD) puncture at 8 weeks of age compared to rats not fed urolithin A |
| 2025-01-30 15-37-02 | Urolithin A slows the reduction in Intervertebral Disc (IVD) histological score at a dose of 25 mg/kg/day when taken for 4 weeks after an IVD puncture at 4-6 months of age compared to rats not fed urolithin A |
| 2025-01-30 15-35-56 | Urolithin A slows the progressive loss of Intervertebral Disc (IVD) height at a dose of 25 mg/kg/day when taken for 4 weeks after an IVD puncture at 12 weeks of age compared to rats not fed Urolithin A |
| 2025-01-30 15-34-35 | Urolithin A slows the progression of Intervertebral Disc (IVD) degeneration at a dose of 25 mg/kg/day when taken for 4 weeks after an IVD puncture at 4-6 months of age compared to rats not fed urolithin A |
| 2025-01-30 15-34-20 | Urolithin A slows the progression of Pfirrmann Grade at a dose of 25 mg/kg/day when taken for 4 weeks after an Intervertebral Disc (IVD) puncture at 12 weeks of age compared to rats not fed urolithin A |
| 2025-01-30 15-33-56 | Urolithin A slows the progression of Intervertebral Disc (IVD) degeneration at a dose of 25 mg/kg/day when taken for 4 weeks after an IVD puncture at 12 weeks of age compared to rats not fed urolithin A |
| 2025-01-30 15-32-27 | Urolithin A slows the progression in Intervertebral Disc (IVD) Pfirrmann Grade at a dose of 25 mg/kg/day when taken for 4 weeks after an IVD puncture at 4-6 months of age compared to rats not fed urolithin A |
| 2025-01-30 15-31-32 | Urolithin A slows the increase in histologic score at a dose of 25 mg/kg/day when taken for 4 weeks after an Intervertebral Disc (IVD) puncture at 12 weeks of age compared to rats not fed urolithin A |
| 2025-01-30 15-30-53 | Urolithin A reduces the serum levels of Matrix Metalloproteinase-3 (MMP3) in mice at a dose of 250 mg/kg/day, but not 50 mg/kg/day, compared to control when taken for 8 weeks after the induction of experimental Osteoarthritis at 4 months of age |
| 2025-01-30 15-26-59 | Urolithin A reduces the knee OARSI score of mice at a dose of 250 mg/kg/day, but not 50 mg/kg/day, compared to control when taken for 8 weeks after the induction of experimental Osteoarthritis at 4 months of age |
| 2025-01-30 15-25-18 | Urolithin A reduces the Intervertebral Disc (IVD) histological score at a dose of 25 mg/kg/day when taken for 4 weeks after an IVD puncture at 8 weeks of age compared to rats not fed urolithin A |
| 2025-01-30 15-24-17 | Urolithin A reduces the Intervertebral Disc (IVD) Pfirrmann Grade at a dose of 25 mg/kg/day when taken for 4 weeks after an IVD puncture at 8 weeks of age compared to rats not fed urolithin A |
| 2025-01-30 15-23-29 | Urolithin A reduces markers of the progression of knee Osteoarthritis at a dose of 250 mg/kg/day, but not 50 mg/kg/day, compared to control when taken for 8 weeks after the induction of experimental Osteoarthritis at 4 months of age |
| 2025-01-30 15-23-01 | Urolithin A may reduce the pain response to a 4g Von Frey filament at a dose of either 250 mg/kg/day or 50 mg/kg/day compared to control when taken for 8 weeks after the induction of experimental Osteoarthritis at 4 months of age |
| 2025-01-30 15-21-19 | Urolithin A may reduce the pain response to a 4g Von Frey filament at a dose of 250 mg/kg/day, but not 50 mg/kg/day, compared to control when taken for 4 weeks after the induction of experimental Osteoarthritis at 4 months of age |
| 2025-01-30 15-20-59 | Urolithin A may reduce the pain from knee Osteoarthritis in mice at a dose of either 250 mg/kg/day or 50 mg/kg/day when taken for 8 weeks after the induction of experimental Osteoarthritis at 4 months of age |
| 2025-01-30 15-18-57 | Urolithin A may reduce knee Sinovitis at a dose of 250 mg/kg/day, but not 50 mg/kg/day, compared to control when taken for 8 weeks after the induction of experimental Osteoarthritis at 4 months of age |
| 2025-01-30 15-18-26 | Urolithin A increases the cell number in non-calcified knee Cartilage of mice at a dose of 250 mg/kg/day, but not 50 mg/kg/day, compared to control when taken for 8 weeks after the induction of experimental Osteoarthritis at 4 months of age |
| 2025-01-30 15-17-08 | Urolithin A increases the Intervertebral Disc (IVD) disc height index at a dose of 25 mg/kg/day when taken for 4 weeks after an IVD puncture at 4-6 months of age compared to rats not fed urolithin A |
| 2025-01-30 15-15-20 | Urolithin A increases the Intervertebral Disc (IVD) Collagen Type II fluorescence at a dose of 25 mg/kg/day when taken for 4 weeks after an IVD puncture at 4-6 months of age compared to rats not fed urolithin A |
| 2025-01-30 15-14-32 | Urolithin A increases the Intervertebral Disc (IVD) Aggrecan fluorescence at a dose of 25 mg/kg/day when taken for 4 weeks after an IVD puncture at 4-6 months of age compared to rats not fed urolithin A |
| 2025-01-30 15-11-44 | Urolithin A can reduce the pain response to a 1g Von Frey filament at a dose of 250 mg/kg/day, but not 50 mg/kg/day, compared to control when taken for 8 weeks after the induction of experimental Osteoarthritis at 4 months of age |
| 2025-01-30 15 28 41 | Urolithin A reduces the progression of Intervertebral Disc (IVD) degeneration at a dose of 25 mg/kg/day when taken for 4 weeks after an IVD puncture at 8 weeks of age compared to rats not fed urolithin A |
| 2025-01-30 14-16-21 | Taking Urolithin A with high-protein yogurt (17 grams) in the morning while fasting does not impact the bioavailability of urolithin A at doses of 500 mg or 1000 mg |
| 2025-01-29 10-52-06 | Daily intraperitoneal injections of 2.5 mg/kg Urolithin A in mice reduce the pain-related behavioral deficits from chronic Sciatic Nerve constriction compared to mice not administered urolithin A when injections begin immediately after constriction surgery |
| 2025-01-29 10-46-32 | Daily intraperitoneal injections of 2.5 mg/kg Urolithin A in mice reduce pain from chronic Sciatic Nerve constriction compared to mice not administered urolithin A |
| 2025-01-29 10-43-15 | A Urolithin A dose of 250 mg/kg/day is likely better than a dose of 50 mg/kg/day at reducing the pain from knee Osteoarthritis in mice when taken for 8 weeks after the induction of experimental arthritis at 4 months of age |
| 2025-01-29 10-42-32 | A Urolithin A dose of 250 mg/kg/day in a mouse equates to 20.3 mg/kg/day in a human |
| 2025-01-29 10-41-13 | A Urolithin A dose of 25 mg/kg/day in a rat equates to 4 mg/kg/day in a human |
| 2025-01-29 10-40-59 | A Urolithin A dose greater than 0.2 mg/kg may relieve pain from constriction of the Sciatic Nerve |
| 2025-01-29 10-39-17 | A Urolithin A dose of 2.5 mg/kg/day in a mouse is equivalent to 0.2 mg/kg/day in a human |